Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
ATAI Life Sciences N.V. (NASDAQ:ATAI) filed an update Friday regarding its planned acquisition of Beckley Psytech Limited, a company based in England and Wales. The update, disclosed in a press release statement and submitted to the Securities and Exchange Commission, provides additional information related to the previously announced share purchase agreement dated June 2, 2025.
Under the agreement, ATAI Life Sciences intends to acquire the entire issued share capital of Beckley Psytech not already owned by ATAI from existing Beckley Psytech shareholders, excluding shares ATAI already holds. The transaction is expected to close in the fourth quarter of 2025, pending approval by ATAI shareholders and satisfaction of customary closing conditions. The company noted that there is no assurance the transaction will be completed within this timeframe or at all.
As part of the filing, ATAI Life Sciences included unaudited interim condensed consolidated financial statements of Beckley Psytech Limited as of June 30, 2025, and for the six months ended June 30, 2025 and 2024. These financial statements were attached as an exhibit to the SEC filing.
ATAI Life Sciences is incorporated in the Netherlands and its common shares are listed on The Nasdaq Stock Market LLC under the symbol ATAI.
The information in this article is based on a press release statement and the company’s Form 8-K filing with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.